文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

早期使用血管加压素对脓毒性休克患者的影响:系统评价与荟萃分析

The effect of early vasopressin use on patients with septic shock: A systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2021-05-06
一句话结论脓毒性休克诊断后6小时内启动血管加压素未降低短期死亡率,但减少肾脏替代治疗使用(OR=0.63)。

该系统评价与荟萃分析纳入5项研究共788例成人脓毒性休克患者,比较诊断后6小时内启动血管加压素输注与未使用或6小时后使用血管加压素的临床结局。主要终点短期死亡率两组无差异(OR=1.09;95%CI 0.8至1.48;P=0.6)。次要终点中,实验组肾脏替代治疗使用较少(OR=0.63;95%CI 0.44至0.88;P=0.007),新发心律失常、ICU住院时间和住院时间两组无统计学显著差异。作者认为仍需大规模随机对照试验评估早期启动血管加压素的获益。

要点

  • 脓毒性休克诊断后6小时内启动血管加压素与对照相比,短期死亡率无差异(OR=1.09;95%CI 0.8至1.48;P=0.6)。
  • 早期血管加压素组肾脏替代治疗使用少于对照组(OR=0.63;95%CI 0.44至0.88;P=0.007)。
  • 新发心律失常两组无统计学显著差异(OR=0.59;95%CI 0.31至1.1;P=0.10)。
  • ICU住院时间无统计学显著差异(平均差=0.16;95%CI -0.91至1.22;P=0.77)。
  • 住院时间无统计学显著差异(平均差=-2.41;95%CI -6.61至1.78;P=0.26)。

适用人群与场景

  • 成人脓毒性休克患者(年龄>16岁)。
  • 实验组为诊断脓毒性休克后6小时内接受血管加压素输注的患者;对照组为未接受血管加压素输注或诊断后6小时接受血管加压素输注的患者。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入随机对照试验和队列研究,共5项研究、788例患者。
  • 主要终点短期死亡率:实验组与对照组无差异(OR=1.09;95%CI 0.8至1.48;P=0.6;χ2=0.83;I2=0%)。
  • 肾脏替代治疗使用:实验组少于对照组(OR=0.63;95%CI 0.44至0.88;P=0.007;χ2=3.15;I2=36%)。
  • 新发心律失常:两组无统计学显著差异(OR=0.59;95%CI 0.31至1.1;P=0.10;χ2=4.7;I2=36%)。
  • ICU住院时间:两组无统计学显著差异(平均差=0.16;95%CI -0.91至1.22;P=0.77;χ2=6.08;I2=34%)。
  • 住院时间:两组无统计学显著差异(平均差=-2.41;95%CI -6.61至1.78;P=0.26;χ2=8.57;I2=53%)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机对照试验和队列研究。
  • 局限:作者指出仍需大规模随机对照试验评估脓毒性休克早期启动血管加压素的获益。

对床旁实践的改变

  • 作者认为,脓毒性休克发作6小时内早期启动血管加压素与短期死亡率降低、新发心律失常减少、ICU住院时间和住院时间缩短无关,但可减少肾脏替代治疗的使用。
  • 作者认为仍需大规模随机对照试验评估脓毒性休克早期启动血管加压素的获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The effect of early vasopressin initiation on clinical outcomes in patients with septic shock is uncertain. A systematic review and meta-analysis was performed to evaluate the impact of early start of vasopressin support within 6 h after the diagnosis on clinical outcomes in septic shock patients.

METHODS: We searched the PubMed, Cochrane, and Embase databases for randomized controlled trials (RCTs) and cohort studies from inception to the 1st of February 2021. We included studies involving adult patients (> 16 years)with septic shock. All authors reported our primary outcome of short-term mortality and in the experimental group patients in the studies receiving vasopressin infusion within 6 h after diagnosis of septic shock and in the control group patients in the studies receiving no vasopressin infusion or vasopressin infusion 6 h after diagnosis of septic shock, clearly comparing with clinically relevant secondary outcomes(use of renal replacement therapy(RRT),new onset arrhythmias, ICU length of stay and length of hospitalization). Results were expressed as odds ratio (OR) and mean difference (MD) with accompanying 95% confidence interval (CI).

RESULTS: Five studies including 788 patients were included. The primary outcome of this meta-analysis showed that short-term mortality between the two groups was no difference (odds ratio [OR] = 1.09; 95% CI, 0.8 to 1.48; P = 0.6; χ2 = 0.83; I2 = 0%). Secondary outcomes demonstrated that the use of RRT was less in the experimental group than that of the control group (OR = 0.63; 95% CI, 0.44 to 0.88; P = 0.007; χ2 = 3.15; I2 = 36%).The new onset arrhythmias between the two groups was no statistically significant difference (OR = 0.59; 95% CI, 0.31 to 1.1; P = 0.10; χ2 = 4.7; I2 = 36%). There was no statistically significant difference in the ICU length of stay(mean difference = 0.16; 95% CI, - 0.91 to 1.22; P = 0.77; χ2 = 6.08; I2 = 34%) and length of hospitalization (mean difference = -2.41; 95% CI, -6.61 to 1.78; P = 0.26; χ2 = 8.57; I2 = 53%) between the two groups.

CONCLUSIONS: Early initiation of vasopressin in patients within 6 h of septic shock onset was not associated with decreased short-term mortality, new onset arrhythmias, shorter ICU length of stay and length of hospitalization, but can reduce the use of RRT. Further large-scale RCTs are still needed to evaluate the benefit of starting vasopressin in the early phase of septic shock.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Huang H, Wu C, Shen Q, et al. The effect of early vasopressin use on patients with septic shock: A systematic review and meta-analysis. Am J Emerg Med. 2021. PMID: 33975132. doi:10.1016/j.ajem.2021.05.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。